The present study examines the effects of the antidepressant venlafaxine, a dual amine reuptake inhibitor, on (a) in vivo regulation of the densities of high-and low-affinity dihydroalprenolol (DHA) binding sites in the cortex of normal and reserpinized Sprague-Dawley rats and (b) targets beyond the beta adrenoceptor. While venlafaxine (30 mg\kg i.p. b.i.d.) administered for 4 d did not alter the DHA-binding parameters in the cortex of normal rats, it significantly reduced, in reserpinized animals, the number of up-regulated low-affinity sites (R L ) which have been tentatively identified as serotonin "B sites. The drug did not influence the up-regulated high-affinity (R H ) DHA-binding sites (beta-adrenoceptor sites). Venlafaxine failed to alter the up-regulated R L sites in brains of rats depleted of serotonin (5-HT) by p-chlorophenylalanine (PCPA) indicating that the normalization by venlafaxine of the up-regulated R L receptor population is mediated by increased synaptic 5-HT. Venlafaxine, given for a short period of time, thus mimicked the action of fluoxetine. While venlafaxine (20 mg\kg i.p. b.i.d.) given for 10 d did not change protein kinase A activity as assessed by the phosphorylation of kemptide in the 900 g supernatant or particulate fractions, the drug significantly reduced phosphorylated cAMP response-element binding protein (CREB-P) in nuclear lysates of cortex after chronic but not acute administration. Depletion of 5-HT by PCPA did not alter the venlafaxine-induced change in nuclear CREB-P. Lastly, analysis of reverse transcribed cortical CREB mRNA by competitive PCR indicated that the mean steady-state levels of CREB mRNA in venlafaxine vs. saline-treated animals were not significantly different. Therefore, since the phosphorylation status of CREB determines its transcriptional activity the reduction of nuclear CREB-P may be venlafaxine's most relevant action beyond the adrenoceptor.
Introduction
Venlafaxine, an ethylcyclohexanol derivative, is a dual amine reuptake inhibitor (Bolden-Watson and Richelson, 1993 ; Muth et al., 1986) which has been demonstrated to be a clinically effective antidepressant with perhaps a faster onset of therapeutic action when compared to tricyclic antidepressants and selective serotonin reuptake inhibitors (Clerc et al., 1996 ; Guelfi et al., 1996 ; Rudolph et al., 1998) . Unlike antidepressants with a strong NE component (MAO inhibitors and secondary amines of tricyclics), venlafaxine does not desensitize the betaadrenoceptor-coupled adenylate cyclase system in the brain except under conditions of selective depletion of brain serotonin (Nalepa et al., 1998) . Interestingly, venlafaxine has been reported to rapidly desensitize the beta-adrenoceptor-coupled adenylate cyclase system to isoproterenol in the pineal gland (Moyer et al., 1984 ; Muth et al., 1991) which is richly innervated by noradrenergic neurons but lacks serotonergic neuronal innervation (Wurtman et al., 1968) . These findings have suggested that desensitization of the beta-adrenoceptorcoupled adenylate cyclase system by antidepressants involves ' cross-talk ' between serotonin (5-HT) and norepinephrine (NE) signal transduction cascades (Nalepa et al., 1998) and perhaps direct action(s) beyond the beta adrenoceptor. In support of this hypothesis, a receptorindependent pharmacological action was demonstrated in vivo for the noradrenergic antidepressant desipramine (DMI) at the level of hippocampal glucocorticoid II receptor mRNA (Eiring and Sulser, 1997 ; Rossby et al., 1995) and in vitro in transfected LTK − or neuroblastoma cells (Pepin et al., 1992) and L-929 mouse fibroblasts (Pariante et al., 1997) .
The present studies were undertaken (1) to determine the relative in vivo actions of venlafaxine in regulating the density of cortical high (beta adrenoceptors) and lowaffinity (5-HT "B ) dihydroalprenolol (DHA) binding sites which are selectively sensitive to the synaptic availability of NE and 5-HT, respectively , and (2) to ascertain venlafaxine's actions on targets beyond the beta adrenoceptor.
Materials and methods

Animals, drug treatment, materials
The experiments reported with Sprague-Dawley rats were conducted in accordance with accepted guidelines and were approved by the Vanderbilt University Animal Care Committee. Male Sprague-Dawley rats (250-300 g) were obtained from Harlan Industries (Indianapolis, IN). They were housed (4-6 per cage) with a controlled light-dark cycle. Food and water were available ad libitum. Rats were treated for 10 d with venlafaxine (20 mg\kg i.p. b.i.d.). Control rats received saline twice daily. Twenty-four hours following the last injection the rats were sedated with a 50\50 mixture of CO # \O # for 1 min and killed by decapitation. The brains were rapidly removed, dissected on ice, frozen in liquid nitrogen, and stored at k70 mC until analysed.
In the studies using the tryptophan hydroxylase inhibitor ,-p-chlorophenylalanine (PCPA), rats received PCPA (200 mg\kg i.p. per day) on days 1, 2, 3, 5, 7, 9, 11 and 13 of the drug treatment period. Beginning on day 4 half of the PCPA group was treated with venlafaxine (20 mg\kg i.p. b.i.d.) and the other half was injected with saline for 10 d. The venlafaxine control group was treated with saline on days 1, 2 and 3 and beginning on day 4 received venlafaxine (20 mg\kg b.i.d.) to day 13.
Reserpine was given in a dose of 1 mg\kg i.p. every third day for 14 d, at which time venlafaxine (30 mg\kg i.p. b.i.d.) was administered for 4 d.
Materials and drugs were obtained as follows : PCPA (,-p-chlorophenylalanine methyl ester), desipramine HCl and reserpine from Sigma Chemical Co., St Louis, MO ; [$H]DHA (specific activity 55 Ci\mmol) from NEN Research Products (Boston, MA), fluoxetine HCl was a gift from Lilly Research Laboratories (Indianapolis, IN), and venlafaxine HCl was generously provided by WyethAyerst Research (Princeton, NJ). Polyclonal antibodies for CREB and CREP-P were obtained from Upstate Biotechnology (Lake Placid, NY). CREB cDNA was a gift from Dr Stephen Hyman, NIMH.
Nonlinear regression analysis of agonist-competitionbinding curves
Competition binding curves were constructed as previously described ) using a concentration of 3 n [$H]DHA and the agonist isoproterenol over a concentration range of 0n001-100 µ. The agonist-competition-binding curves were subjected to nonlinear regression analysis using the program  (Munson and Rodbard, 1980) .
Assay of protein kinase A (PKA) activity
PKA activity was determined essentially according to the protocol supplied by Gibco-BRL (Grand Island, NY). Tissue or cells were disrupted with a glass homogenizer in 1 ml of homogenization buffer (0n32  sucrose ; 10 m KH # PO % ; 5 m MgCl # ; 150 m NaCl ; pH 6n5). Supernatant and particulate fractions were separated by centrifugation at 900 g for 10 min. Four assay conditions were used : (1) total PKA activity (plus 100 µ cyclic AMP) with and without PKA inhibitor, and (2) endogenous activity (no cyclic AMP added) with and without PKA inhibitor. Total incubation volume was 80 µl in TrisMgCl # buffer. After incubation for 5 min at 30 mC, 20 µl aliquots were spotted onto phosphocellulose paper (2i2 cm, Whatman P81). The filter squares were washed twice for 5 min in 75 m H $ PO % and twice for 5 min in H # O and then counted by liquid scintillation spectrometry. PKA activity was defined as the transfer of PO % from ATP (100 µ, $#P-tracer 300 cpm\pmol) to the heptapeptide Kemptide (50 µ) and normalized per units protein and time. Proteins were quantitated according to Lowry et al. (1951) .
Preparation of nuclear extracts
Nuclear extracts were prepared according to the method of Wuarin and Shibler (1990) . Briefly, assay material was homogenized in 5 % citric acid in a glass Teflon homogenizer. After centrifugation (1500 g, 5 min) the resulting pellet was resuspended in 5 % citric acid containing 0n5% Triton X-100, and homogenized in a Dounce homogenizer. Nuclei were centrifuged through a sucrose cushion containing 5 % citric acid and 30 % sucrose at 1500 g for 5 min. The purified nuclei were resuspended in 1 % citric acid and aliquots were taken for protein determinations. An equal volume of lysis solution (0n1  Tris buffer, 2n5 % SDS, 0n1  DTT; pH 7n5) was added and heated to 90 mC for 10 min. Nuclear lysates were frozen at k80 mC for later assay or subjected to gel electrophoresis.
Determination of nuclear CREB and CREB-P
Nuclear CREB and CREB-P were assayed by subjecting nuclear lysates to gel electrophoresis followed by immunoblotting using polyclonal anti-CREB and anti-CREB-P antibodies (Upstate Biotechnology, Lake Placid, NY) Figure 1 . Demonstration of identical amplification efficiencies for T7 CREB and T7 CREB-INS plasmids. Three concentrations of the wild-type CREB-containing plasmid T7 CREB (10, 1, 0n1 pg) were each co-amplified with a serial dilution of the competitive standard T7 CREB-INS (100, 10, 1, 0n1, 0n01 pg). Band densities were quantitated directly from the gel. Two bands corresponding to the expected sizes of the products from T7 CREB (604 bp) and T7 CREB-INS (704 bp) were confirmed. The intensities of the bands derived from T7 CREB-INS decreased while those derived from T7 CREB increased demonstrating competition for primers. At the T7 CREB-INS concentration which produced upper and lower bands of equal density (determined by linear regression analysis, see Materials and methods) the starting concentrations of the two cDNAs (before amplification by PCR) were taken to be equivalent (A, lane 2 ; B, lane 3, C, lane 4).
according to the supplier's protocol. Antibody-antigen complexes were detected by enhanced chemiluminescence followed by autoradiography and quantitated by laser densitometry.
Competitive PCR (cPCR) analysis of CREB mRNA
Total RNA was isolated and purified from cortex by the method of Chomczynski (1993) utilizing TRI reagent, and RNA quantity and purity were determined by spectrophotometry (Pharmacia Ultrospec III) and RNA gel electrophoresis.
Competitive PCR was performed with primer CREB-N1 of genomic polarity (5h-TTCAGTCTCCACAAGT-CC-3h-and primer CREB-2 of antigenomic polarity (5h-AGGCTGTGTAGGAAGTGC-3h). A competitive template (internal standard) was constructed from the rat T7 CREB plasmid (generously provided by Dr Steven E. Hyman) containing a 1n24 kb CREB coding sequence plus approx. 150 bp of 5h and 50 bp of 3h untranslated sequences cloned into pGEM β3Zf(k). The plasmid was linearized with StuI which cuts at nt 432 of the CREB sequence producing blunt ends -followed by removal of 5h phosphates with calf intestinal phosphatase (CIP) to prevent self-ligation in the following step. Next the plasmid was recircularized by ligation of a 100 bp DNA insert (isolated from the BRL 100 bp ladder) in low melting temperature (LMT) agarose. The resultant subclone T7 CREB-INS has the same primer annealing sites as the parent clone T7 CREB ; but is longer by 100 bp.
Synthesis of cDNA from total cortex RNA was performed in a volume of 20 µl containing 100 U MMLV reverse transcriptase, 0n5 m dNTP, 5 µm oligo(dT ") ), 1n5 µg RNA, 10 U placental RNase inhibitor, and 1iRT transcription buffer. The cDNA product was amplified in a total volume of 40 µl containing 0n1 m dNTP, 8 µ of each primer, 4 µl T7 CREBS-INS, 4 µl RT product, 0n4 µl Amplitaq and 1iPCR buffer. The reaction was performed in a PTC Thermal Controller (MJ Research Inc., Watertown, Mass.) as follows : 94 mC\20 s, 55 mC\30 s, 72 mC\40 s, for 25 cycles followed by 72 mC\5 min (Ambion kit for RT, Qiagen for Taq polymerase kit). Three amounts of DNA from the wild-type CREBcontaining plasmid [T7 CREB (10, 1, 0n1 pg)] were each co-amplified for 30 cycles with a standard series of decreasing amounts of the competitive template, T7 CREB-INS (Figure 1 ). The amplified reaction mixtures were analysed by electrophoresis in a 2n0 % agarose gel containing ethidium bromide and visualized by UV fluorescence. Band densities were quantitated directly from the gel on a digital imaging system (Alpha Innotech Corporation, San Leandro, CA). The two bands corresponding to the expected sizes of the products from T7 CREB (604 bp) and T7 CREB-INS (704 bp) were confirmed. The intensities of the bands derived from T7 CREB decreased while those derived from T7 CREB-INS increased, also as expected, demonstrating competition for primers. At the point where the upper and lower band densities were equivalent, i.e. ratio l 1 : 1 (determined by linear regression analysis, see below), the known starting concentration (prior to PCR) of T7 CREB was found to be equal to the known starting concentration of the competitor T7 CREB-INS ( Figure 1A , lane 2 ; Figure 1B , lane 3 ; and Figure 1C, lane 4) .
Results
Effect of venlafaxine on the R H and R L population of DHA-labelled receptors in frontal cortex : nonlinear regression analysis of agonist-competition-binding curves
In agreement with previous studies , nonlinear regression analysis of agonist-competitionbinding curves, using [$H]DHA as the radioligand and (k)-isoproterenol as the agonist, demonstrated that in normal cortical tissue about 77 % of beta adrenoceptors labelled by DHA, have high (nanomolar) affinity for isoproterenol (R H ) and the remaining 23 % of the receptors (R L ) display low (micromolar) affinity for isoproterenol (Table 1) . Chronic administration of reserpine caused a In order to discover the mechanism of venlafaxine's effect on R L in reserpine-treated animals we conducted a series of experiments in which the density of R L was increased by treatment with PCPA. In the virtual absence of 5-HT (our PCPA treatment schedule selectively depletes brain 5-HT by 95-97 % ; Nalepa et al., 1998 ; Rossby et al., 1995) , venlafaxine (20 mg\kg i.p. b.i.d.) given for 10 d did not alter the number of up-regulated R L ( Table 2 ), indicating that the normalization of the upregulated R L receptor population by venlafaxine was mediated via 5-HT.
Effect of venlafaxine on protein kinase A activity in the 900 g supernatant and particulate fractions of cortex
To ascertain whether venlafaxine alters signal transduction beyond the second messenger cyclic AMP, PKA activity was determined in the 900 g supernatant and particulate fractions. The data in Table 3 indicate that venlafaxine (20 mg\kg i.p. b.i.d. for 10 d) did not significantly alter cyclic AMP-stimulated PKA activity in either the 900 g supernatant or the particulate fraction. (11) 2010p93 (11) 258p34 (9) 592p72 (9) Venlafaxine 821p74 (11) 1918p31 (11) 219p48 (9) 517p103 (9) Rats were treated for 10 d with venlafaxine (20 mg\kg i.p. b.i.d.). Animals were killed 16 h after the last drug dose and PKA activity determined in the 900 g supernatant and particulate fractions in the presence or absence (endogenous) of 100 µ cyclic AMP as described in Materials and methods. The numbers in parentheses indicate the number of animals. There was also no indication of a translocation of PKA activity from the supernatant to the particulate fraction.
Effect of venlafaxine on nuclear CREB phosphorylation in cortex
Previous results have suggested that venlafaxine causes a deamplification of the cyclic AMP cascade by a mechanism beyond the beta adrenoceptor (Nalepa et al., 1998) . Accordingly, we analysed nuclear CREB phosphorylation in the frontal cortex of rats treated with venlafaxine for 1 show that treatment for 10 d significantly reduced CREB-P in nuclear lysates. Total CREB in nuclear lysates of frontal cortex was, however, not altered. Also, acute treatment with venlafaxine (1 d) did not change the phosphorylation status of CREB (data not shown).
Since venlafaxine exerts potent serotonergic activity (see previous results in this paper), the action of venlafaxine on nuclear CREB-P was determined in PCPA pre-treated animals. The results ( Figure 2B ) demonstrate that depletion of 5-HT did not alter the venlafaxineinduced change in nuclear CREB-P, suggesting that this action of the drug does not depend on the synaptic availability of 5-HT.
Effect of venlafaxine on cortical CREB mRNA using cPCR
Following the demonstration of identical amplification efficiencies for the T7 CREB and T7 CREB-INS plasmids, samples of cDNA reverse transcribed from cortical RNA isolated from saline-and drug-treated rats were coamplified with a series of known concentrations of the competitive template T7 CREB-INS. The PCR products were subsequently electrophoresed and band densities determined as described (Figure 3) .
Mean steady-state levels of CREB mRNA in rat cortex were almost identical in venlafaxine-treated (n l 7) vs. saline-treated (n l 8) animals as determined by a twotailed Student's t test (p l 0n7580).
Discussion
Studies with venlafaxine conducted in animals with selective depletion of brain 5-HT by PCPA have suggested cross-talk between noradrenergic and serotonergic signal transduction cascades at the level of mechanisms involved in the desensitization of the beta-adrenoceptorcoupled adenylate cyclase system (Nalepa et al., 1998) . To determine the relative in vivo activity of venlafaxine in increasing the synaptic availability of 5-HT and NE in brain, the reserpine-induced up-regulation of high-and low-affinity sites for the beta-adrenoceptor antagonist DHA was utilized as a biochemical test model. Nonlinear regression analysis of agonist-competition-binding curves has revealed that DHA labels two sites, one with high (nanomolar) affinity for isoproterenol (beta adrenoceptors), and another with low (micromolar) affinity for isoproterenol tentatively identified as 5-HT "B sites . Both sites are up-regulated by reserpine and are very sensitive to the synaptic availability of NE and 5-HT, respectively .
In the present experiments, venlafaxine normalized the up-regulated 5-HT sensitive low-affinity sites (R L ) but failed to alter the up-regulated NE sensitive high-affinity sites (R H ) which in contrast are normalized by the NE reuptake inhibitor desipramine . Venlafaxine in the doses used thus mimics the pharmacological action of fluoxetine . The demonstrated lack of effect of venlafaxine on low-affinity sites in the rat brain depleted of 5-HT by PCPA provides evidence that this action of the drug is mediated by 5-HT. It cannot be ruled out, however, that larger doses of venlafaxine or venlafaxine administered for a longer period of time could have affected the NE-sensitive highaffinity beta-adrenoceptor sites. It has been hypothesized that the lack of beta-adrenoceptor down-regulation after chronic administration of venlafaxine might be the consequence of the drug's activation of protein kinase C via the 5-HT #A/#C receptor cascade (Nalepa et al., 1998) . In support of this notion Do$ bbeling and Berchtold (1996) have demonstrated down-regulation of the PKA pathway in a fibroblast cell line by protein kinase C activation. Since beta adrenoceptor down-regulation and\or desensitization of the beta-adrenoceptor-coupled adenylate cyclase system are accomplished in part by receptor phosphorylation via PKA (Lefkowitz, 1993) , down-regulation of PKA could explain, at least in part, the lack of effect on beta adrenoceptors after chronic administration of venlafaxine. However, under the present experimental conditions neither endogenous nor cyclic AMP-stimulated PKA activity was changed in the 900 g supernatant or particulate fractions in vitro following venlafaxine treatment, and there was no indication of a translocation of PKA from the soluble to the particulate fraction, as reported following chronic administration of some antidepressants (Nestler et al., 1989) .
However, investigation of CREB phosphorylation (activation) revealed significant decreases in CREB-P in nuclear lysates (cortical) following chronic treatment with venlafaxine. Although the mechanism responsible for this decrease in nuclear CREB-P is presently unclear it is intriguing because the concentration of nuclear CREB-P determines (or strongly influences) the levels of expression of genes containing CREs in their regulatory regions (Gonzalez and Montminy, 1989 ; Yamamoto et al., 1988) .
Finally, whereas phosphorylation\dephosphorylation is generally considered to be the primary mechanism of CREB regulation, the extent to which CREB gene expression plays a role (if any) in its response to second messenger cascades, i.e. induced by antidepressant drugs has been difficult to determine by standard techniques (Meyer and Habener, 1993 ; Muller et al., 1995) , suggesting that the CREB gene is either expressed at barely detectable basal levels or its mRNA is rapidly degraded. In fact data showing extremely low levels of CREB mRNA in many cell types has led to speculation that CREB is constitutively expressed, i.e. unmodulated by signal transduction mechanisms. And although this presumption was invalidated, initially by two studies reporting developmental modulation of CREB gene expression during spermatogenesis (Ruppert et al., 1992 ; Waeber et al., 1991) , and more recently by Muller et al. (1995) and Nibuya et al. (1996) , assaying changes in CREB mRNA levels in mature, terminally differentiated tissues has remained problematic. Against this background the cPCR methodology utilized in the present study produced very robust signals and demonstrated that the mechanism of action of venlafaxine does not involve regulation of CREB mRNA levels. This lack of effect of venlafaxine on CREB mRNA levels, assayed by sensitive cPCR methodology, does not support the notion that up-regulation of CREB is a common action of chronic antidepressant treatments (Nibuya et al., 1996) . However, our results may indicate alternatively that the pharmacological action of venlafaxine beyond the receptors is distinctly different from that of other antidepressants. Moreover, the functional relevance of any changes in CREB mRNA is difficult to assess, since phosphorylation\dephosphorylation of CREB rather than its abundance determines its level of transcriptional activity (Meyer and Habener, 1993) . The reduction of nuclear CREB-P reported here may thus be venlafaxine's most relevant pharmacological action beyond the receptors. Accordingly it is tempting to speculate that decreased nuclear CREB-P is responsible for the net deamplification of aminergic signal transduction cascades following chronic administration of venlafaxine.
